Drug Safety Concerns Shape Manufacturing Policy

FDA wants manufacturers to revise product labeling and packaging and step up adverse-event monitoring to reduce risky product use.

Related Content:

Regulatory Oversight and CompliancePharmaceutical Technology-03-02-2002

FDA Posts Slate of Seven Warning Letters Following Company Inspections

FDA Approves New Moderna COVID-19 Vaccine mNEXSPIKE

Geopolitical Shifts Change Nature of Pharma Partnerships